GH receptor antagonist: mechanism of action and clinical utility.
This review focuses on the development of GH receptor antagonist as a novel agent for treatment of acromegaly, its mechanism of action and potential areas of use. A brief overview of acromegaly, its diagnosis and existing medical, surgical and radiotherapy options of treatment is necessary to justify the addition of yet another therapeutic modality to the already vast therapeutic armamentarium.
Surya
Sowmya K
SK
Division of Endocrinology, University of Michigan Hospitals, 3920 Taubman Center, Box 0354, 1500 E. Medical Center Drive, Ann Arbor, MI 48109, USA.
Barkan
Ariel L
AL
D000172:Acromegaly / Q000175:diagnosis / Q000188:drug therapy* / Q000628:therapy; D000818:Animals; D003928:Diabetic Nephropathies / Q000188:drug therapy; D006727:Hormone Antagonists / Q000627:therapeutic use*; D019382:Human Growth Hormone / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000502:physiology; D009369:Neoplasms / Q000188:drug therapy; D011986:Receptors, Somatotropin / Q000037:antagonists & inhibitors*; D013004:Somatostatin / Q000031:analogs & derivatives*
D006727:Hormone Antagonists; D011986:Receptors, Somatotropin; D019382:Human Growth Hormone; D013004:Somatostatin; D007334:Insulin-Like Growth Factor I; C406545:pegvisomant